Advertisement Advertisement Inclusion of genomic profiling and risk factors recommended for treatment planning Large retrospective analysis may prompt prospective studies Robust signal from observational study raises prospect of a long-sought medical therapy Post hoc analysis of SURPASS-CVOT trial has implications for future cardiovascular outcome trials Retrospective analysis finds lower mortality rates, fewer hospital visits among patients with Type 1 diabetes using GLP-1 Therapies Observational evidence of neuroprotection with GLP-1 receptor agonists and SGLT-2 inhibitors Study is first to show reduction in autoimmune disease with the common diabetes and obesity drugs Surgical intervention linked to increased lifespan and reduced complications
Importantly, this pathway is enzymatically tractable, as the enzymes that control CoQ 10 reduction are druggable oxidoreductases, making the CoQ 10 axis a promising pharmacological entry point for ferroptosis-based cancer therapy
found that the transcription factor ChREBP can also promote BCKDK and inhibit PPM1K expression to inhibit BCKDH activation and promote ATP citrate lyase (ACLY) activation, upregulate the lipid synthesis pathway, and induce hepatic steatosis in the obesity model of high-sugar diet
10.2337/dc13-2855 46 LingvayI.Prez ManghiF.Garca-HernndezP.NorwoodP.LehmannL.Tarp-JohansenM
When to Consider a Higher Dose: Balancing Hunger and Weight Loss on Wegovy Finding the perfect balance between hunger management and weight loss results often requires careful consideration of Wegovy dosing strategies
This data helps providers optimize your GLP-1 dose and understand how your genetics interact with testosterone therapy
